US 6774122B2
· Evans et al.
· 2004
[cited by applicant]
US 7456160B2
· Evans et al.
· 2008
[cited by applicant]
US 8158152B2
· Palepu
· 2012
[cited by applicant]
US 8329680B2
· Evans et al.
· 2012
[cited by applicant]
US 8466139B2
· Evans et al.
· 2013
[cited by applicant]
US 8541400B2
· Johnsson et al.
· 2013
[cited by applicant]
US 8586092B2
· Hu et al.
· 2013
[cited by applicant]
US 8853260B2
· Desai et al.
· 2014
[cited by applicant]
US 8956659B2
· Hu et al.
· 2015
[cited by applicant]
US 9180088B2
· Palepu
· 2015
[cited by applicant]
US 9254268B2
· Temtsin et al.
· 2016
[cited by applicant]
US 9271990B2
· Faraj
· 2016
[cited by applicant]
US 20010020016A1
· Evans et al.
· 2001
[cited by applicant]
US 20030114430A1
· Macleod et al.
· 2003
[cited by applicant]
US 20030165568A1
· Colombo et al.
· 2003
[cited by applicant]
US 20100166872A1
· Singh et al.
· 2010
[cited by applicant]
US 20100323020A1
· Gokhale et al.
· 2010
[cited by applicant]
US 20130033813A1
· Ling et al.
· 2013
[cited by applicant]
US 20140314664A1
· Qin et al.
· 2014
[cited by applicant]
US 20150104521A1
· Desai et al.
· 2015
[cited by applicant]
US 20150132388A1
· Angi et al.
· 2015
[cited by applicant]
US 20160220505A1
· Temtsin et al.
· 2016
[cited by applicant]
CN 1429101A
· 2003
[cited by applicant]
CN 101108168A
· 2008
[cited by applicant]
CN 102802609A
· 2012
[cited by applicant]
CN 104337761A
· 2015
[cited by applicant]
EP 1962906
· 2008
[cited by applicant]
EP 2200588
· 2010
[cited by applicant]
EP 2249839
· 2010
[cited by applicant]
EP 2460539A1
· 2012
[cited by applicant]
EP 2601935A1
· 2013
[cited by applicant]
EP 2616078
· 2013
[cited by applicant]
EP 2661281
· 2013
[cited by applicant]
EP 3068377
· 2016
[cited by applicant]
JP 2003519659A
· 2003
[cited by applicant]
JP 2004534093A
· 2004
[cited by applicant]
TW 201016220A
· 2010
[cited by applicant]
WO 0187266A1
· 2001
[cited by applicant]
WO 0306064
· 2003
[cited by applicant]
WO 2006013369A2
· 2006
[cited by applicant]
WO 2007061529A1
· 2007
[cited by applicant]
WO 2007069272A2
· 2007
[cited by applicant]
WO 2009040818A1
· 2009
[cited by applicant]
WO 2009111057A2
· 2009
[cited by applicant]
WO 2010147899A1
· 2010
[cited by applicant]
WO 2012021791A2
· 2012
[cited by applicant]
WO 2012035516A1
· 2012
[cited by applicant]
WO 2012094620A2
· 2012
[cited by applicant]
WO 2013153559A1
· 2013
[cited by applicant]
WO 2015033302A2
· 2015
[cited by applicant]
WO 2015051193A1
· 2015
[cited by applicant]
WO 2015071836A1
· 2015
[cited by applicant]
WO 2015114320A1
· 2015
[cited by applicant]
WO 2016000653A1
· 2016
[cited by applicant]
WO 2016004369A1
· 2016
[cited by applicant]
Addo et al., A phase 1 trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers, British Journal of Cancer, 87, 2002, 1354-1359.
[cited by applicant]
Ballard, B., “Biopharmaceutical considerations in subcutaneous and intramuscular drug administration”, Journal of Pharmaceutical Sciences, 1968, 57(3):357-378.
[cited by applicant]
Behre, H., et al., “Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies”, 1999, 140(5):414-419.
[cited by applicant]
Brunner, N. “MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780”, Cancer Res. 1993, 53(14):3229-3232.
[cited by applicant]
Chatterjee et al., Contrasting action of antiestrogen (ICI-182780) for preventing initiation of embryo implantation by estradiol or epidermal growth factor (EGF). Life sciences, Jan. 1, 1993;53(21):1625-1630.
[cited by applicant]
DeFriend et al., Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research. Jan. 15, 1994;54(2):408-414.
[cited by applicant]
Dukes et al., Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys, Journal of Endocrinology. Nov. 1, 1992;135(2):239-247.
[cited by applicant]
Dukes et al., Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (
[cited by applicant]
Gallagher et al., The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology. Dec. 1, 1993;133(6):2787-2791.
[cited by applicant]
Gradishar et al., Clinical potential of new antiestrogens. Journal of Clinical Oncology. Feb. 1997;15(2):840-852.
[cited by applicant]
Gunther et al., The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatric research. Sep. 1999;46(3):269-273.
[cited by applicant]
Howell et al., Clinical studies with the specific ‘pure’ antioestrogen ICI 182780. The Breast. Jun. 1, 1996;5(3):192-195.
[cited by applicant]
Hu et al., Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780. International journal of cancer, Nov. 11, 1993;55(5):873-876.
[cited by applicant]
ISO 13320, International Standard, Particle size analysis—Laser diffraction methods; First edition, Oct. 1, 2009, 58 pages.
[cited by applicant]
Kern, F. et al., “Transfected MCF-7 cells as a model for breast cancer progression”, Breast Cancer Research and Treatment, 1994, 153-165.
[cited by applicant]
Kuter et al., Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study, Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 26, No. 15S, (May 20 …
[cited by applicant]
Langdon, S. et al., “Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model”, Eur J Cancer, 1994, 682-686.
[cited by applicant]
McClelland, R. et al., “Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes”, Breast Cancer Research Treatment, 1996, 41…
[cited by applicant]
McClelland, R. et al., “Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast canc…
[cited by applicant]
Minto, C., et al., “Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume”, The Journal of Pharmacology and Experimental Therapeutics, 1997, 281…
[cited by applicant]
Nicholson, R. et al., “Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer”, Annals New York Academy of Sciences, 1995, 12;761:148-163.
[cited by applicant]
Ogasawara , Y. et al., “Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice”, Surgery Today, 1999, 29, 149-156.
[cited by applicant]
Ohno et al., Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1), Annals of Oncology 21: 2342-2347, 2010.
[cited by applicant]
Osborne, C. et al., “Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer”, Journal of the National Cancer Institute, 1995, 746-750.
[cited by applicant]
Osborne, C., et al., “The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth”, Cancer Chemother Pharmacol, 1994, 89-95.
[cited by applicant]
Parczyk, K., et al., “Progesterone receptor repression by estrogens in rat uterine epithelial cells”, J Steroid Biochem Mol Biol., 1997, 63(4-6):309-316.
[cited by applicant]
Parisot, J. et al., “The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor”, Int J Cancer, 1995, 62(4):480-4.
[cited by applicant]
Robertson et all., Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer, Clin. Pharmacokinet, 43(8), 2004, 529-538.
[cited by applicant]
Robertson, Fulvestrant: pharmacokinetics and pharmacology; British Journal of Cancer, 90 (Suppl I), 2004, S7-S10.
[cited by applicant]
Sahlin, L., et al., “Regulation of thioredoxin mRNA in the rat uterus by gonadal steroids”, Journal of Steroid Biochemistry & Molecular Biology, 1999, 68(5-6):203-209.
[cited by applicant]
Spiegel, A., et al., “Use of Nonaqueous Solvents in Parenteral Products”, Journal of Pharmaceutical Sciences, 1963, 52, 917-927.
[cited by applicant]
Thurlimann, B., “Hormonal treatment of breast cancer: new developments”, Oncology, 1998, 55(6):501-507.
[cited by applicant]
Vollmer, G., et al., “The rat endometrial adenocarcinoma cell line RUCA-I: a novel hormone-responsive in vivo/in vitro tumor model”, J Steroid Biochem Mol Biol. 1996, 58(1):103-115.
[cited by applicant]
Von Minckwitz, G. et al., “New endocrine approaches in the treatment of breast cancer”, Biomed Pharmacother, 1998, 52(3):122-132.
[cited by applicant]
Wakeling AE. A new approach to breast cancer therapy: Total estrogen ablation with pure antiestrogens, Long-Term Tamoxifen Treatment for Breast Cancer, ed Jordan VC (University of Wisconsin Press, Madison). 1994:219-234.
[cited by applicant]
Wakeling, A., “Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?”, The Journal of Steroid Biochemistry and Molecular Biology, 1993, 107-114.
[cited by applicant]
Wakeling, A., “Interactions Between Growth Factors and Oestrogens in Breast Cancer Cells”, Molecular Oncology and Clinical Applications, 1993, 385-389.
[cited by applicant]
Wakeling, A., “The future of new pure antiestrogens in clinical breast cancer”, Breast Cancer Res Treat. 1993, 25(1):1-9.
[cited by applicant]
Wakeling, A., et al., “Development of novel oestrogen-receptor antagonists”, Biochem Soc Trans, 1991, 19(4):899-901.
[cited by applicant]
Wakeling, A., et al., “ICI 182,780, a new antioestrogen with clinical potential”, J Steroid Biochem Mol Biol. 1992, 43(1-3):173-177.
[cited by applicant]
Wilson, J. et al., “MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage”, Int J Cancer, 1995 , 61(4):502-508.
[cited by applicant]
Zalcberg, J. et al., “Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines”, Cancer Chemother Pharmacol. 1993;33(2):123-129.
[cited by applicant]
“Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution”, Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ef00202d-7a97-43df-adc7-c4043b54df03, Retrieved on Feb. 18, …
[cited by applicant]
“Polyethylene Glycol 3350”, Revision Bulletin, Dec. 1, 2020, 7 Pages.
[cited by applicant]